Founded in 2023, the company centers its development on the proprietary ATTOBODY biologics platform, licensed from Alamar Biosciences. This technology utilizes an evolution-based, high-throughput workflow to engineer complex mono-, bi-, and trispecific biologics. The capital injection from this IPO is earmarked primarily for advancing the firm’s core clinical pipeline, which includes candidates ATTO-1310, ATTO-2306, and ATTO-1091.

Dr. Kan Chen, partner at Qiming Venture Partners, noted that the platform addresses significant gaps in current standards of care for immune-mediated conditions. Having supported the company since its inception, the venture firm views the public listing as a critical transition point for moving platform technology into broader clinical-stage applications. Qiming Venture Partners, which manages $9.5 billion in capital, continues to focus on early-stage biotech innovation, adding Attovia to a portfolio that includes over 210 companies with successful public exits.